The results were presented at a symposium during the American Diabetes Association's 84th Scientific Sessions in Orlando, Florida, and mark the first large-scale trial specifically designed to investigate the effect of fenofibrate on eye outcomes in people with early diabetic retinopathy.
OCU410ST is a modifier gene therapy candidate being developed for Stargardt disease, which affects approximately 100,000 people in the United States and Europe combined.
Researchers at Washington University School of Medicine in St. Louis for years have worked to understand the rare condition known as retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations.
OCU400 is a gene-agnostic modifier gene therapy product based on nuclear hormone receptor (NHR) gene, NR2E3.
The second and third required PPQ batches are scheduled, and should they meet specifications, the new TRIESENCE production process will be complete, allowing Harrow to relaunch during 2024.
A priority review has been granted with a PDUFA goal date set for December 17, 2024.
According to the companies, the partnership will accelerate the development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-related macular degeneration.
Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.
VISTA is a global randomly assigned, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa
Researchers from the Case Western Reserve University School of Medicine and the Cole Eye Institute have found that supplement melatonin could be linked to a decreased risk of age-related macular degeneration.
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than the standard bimonthly aflibercept control group at all 6 time points through Week 24.
Jennifer Lim, MD, FARVO, spoke with us about her presentation Faricimab vs aflibercept in the reduction of exudates in Y/R trials" at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.
Carl Danzig, MD, spoke with us about his presentation on the 24 week results of the PRISM trials for wet AMD. He gave this presentation at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.
Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.
The primary endpoint for the ReNEW and ReGAIN trials is the rate of change in the macular area of photoreceptor loss assessed by spectral domain-optical coherence tomography (SD-OTC) and ellipsoid zone mapping at week 48.
The company noted its OCT reference database now offers a library of 870 healthy eyes, more than tripling the previous versions.
The electromagnetic driving systems are proposed for the flexible 5-DOF magnetic manipulation of a micro-robot within the posterior eye, enabling precise targeted drug delivery.
Ocugen is developing OCU410 as a 1-time gene therapy for the treatment of geographic atrophy. It utilizes an AAV delivery platform for the retinal delivery of the ROR Related Orphan Receptor A gene.
EyeBio is developing a pipeline of clinical and preclinical candidates for the prevention and treatment of vision loss associated with retinal vascular leakage.
The COVID-19 pandemic changed medicine forever, and now scientists are forging a new path for healthcare in the future, including in ophthalmology.
According to researchers at Waseda University in Japan, the proposed device can measure electrical potentials from different places in the retina simultaneously, which is useful in diagnosing eye diseases.
Understanding how the intricate networks of blood vessels in the eye and brain are formed ultimately could inspire new treatments for conditions like diabetic retinopathy and stroke.
Researchers note the G90D mutation in rhodopsin is known to produce background electrical noise to desensitize rods, but the nature of the ‘noise’ and its precise molecular source have not been resolved for almost 30 years.
The campaign will encourage, educate and empower the public to include vision and eye health as a part of their healthcare by asking them to share how eye care services and exams improved their vision and their daily lives.
According to ophthalmologists at the Colorado University School of Medicine, discussing mental well-being is a key part of effective treatment and improving care for patients.
At this year's ARVO meeting, Edmund Tsui, MD, presented a paper on the analysis of anterior chamber inflammation through automated quantitative assessment of swept-source anterior segment OCT images.
At this year's ARVO meeting, Roger Goldberg, MD, presented a paper on hard exudates and their resolution in patients with diabetic macular edema treated with either faricimab or 2 mg aflibercept.
At this year's ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, presented a paper on predicting functional outcomes for different treatment durations of faricimab in diabetic macular edema.
At this year's ARVO meeting, Irene Santiago Tierno, MS, talked with Ophthalmology Times about the paper she presented on how abnormal subendothelial matrix exacerbates choroidal endothelial cell death in early age-related macular degeneration.
The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene.
